111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Acasunlimab (Aca; DuoBody-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor immunity via conditional 4-1BB activation dependent on co-PD-L1 binding. A ph 2 study of Aca in patients (pts) with PD-L1+ mNSCLC (NCT05117242) showed an acceptable safety and efficacy profile. Given historical immune-related risks with 4-1BB agents, proactive management of immune-related risks (PMIR) was implemented. We report the effects of PMIR on mitigation and management of immune-related hepatic adverse events (IRHAEs).

Authors

Institutions

Publication Details

Journal
ESMO Open
Published
2026-03-17
DOI
https://doi.org/10.1016/j.esmoop.2026.106418
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Federico Cappuzzo, Yanhong Zhou, Gilles Quéré, Tomer M. Mark et al.
ESMO Open
Cancer Immunotherapy and Biomarkers
article

111P Proactive management of immune-related hepatic events in a phase II trial of acasunlimab plus pembrolizumab in patients with mNSCLC

Federico Cappuzzo, Yanhong Zhou, Gilles Quéré, Tomer M. Mark, C. Helissey, T.C. Wehler, T.J. Ong, J.G. Aerts, S. Gadgeel, L. Paz-Ares, A. Araújo, M.J. Chisamore, J.C. Benitez, F. Guisier, E. Felip, B. Besse, W. Theelen, D.M. Kowalski
article en

Abstract

Acasunlimab (Aca; DuoBody-PD-L1x4-1BB) is a bispecific antibody immunotherapy designed to reinvigorate antitumor immunity via conditional 4-1BB activation dependent on co-PD-L1 binding. A ph 2 study of Aca in patients (pts) with PD-L1+ mNSCLC (NCT05117242) showed an acceptable safety and efficacy profile. Given historical immune-related risks with 4-1BB agents, proactive management of immune-related risks (PMIR) was implemented. We report the effects of PMIR on mitigation and management of immune-related hepatic adverse events (IRHAEs).

ESMO OpenVol. 11
Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Inserm (FR), Genmab (United States) (US), Universitätsklinikum Gießen und Marburg (DE), Université Paris-Saclay (FR), Institut Gustave Roussy (FR), Erasmus MC (NL), Henry Ford Hospital (US), The Netherlands Cancer Institute (NL), Hospital Universitario 12 De Octubre (ES), Hôpital Saint Joseph (FR), National Institute of Oncology (HU), Hospital de Santo António (PT), Vall d'Hebron Hospital Universitari (ES), Centre Hospitalier Régional Universitaire de Brest (FR), Istituti Fisioterapici Ospitalieri (IT), Institute for Research and Innovation in Biomedicine (FR), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Centre Hospitalier Universitaire de Rouen (FR), Centro Hospitalar do Porto (PT), Hospital Clínico Universitario Virgen de la Victoria (ES), Université de Rouen Normandie (FR)
Good health and well-being
Openalex Percentile: Top 19%
Cancer Immunotherapy and Biomarkers
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.